Dr. Guy Boivin is a professor in the Department of Pediatric of the Faculty of Medicine at Laval University. He held the Canada Research Chair in Emerging Viruses and Antiviral Resistance during 14 years, as well as a « Foundation » grant from the Canadian Institutes of Health Research (CIHR) for 7 years. He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccines in the elderly. 

Dr. Boivin is the author or co-author of over 400 scientific publications and 390 presentations at various international conferences and symposia. He has also contributed to the creation of 17 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections and of the company Vaxxel, that develops vaccines against respiratory viruses. He is the director of a NC3 laboratory that is operational since 2020, which expands the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (SARS-CoV-2). He is also the co-director of the international lab RespiVir jointly with Dr Rosa-Calatrava from Lyon, France. 

His research program focuses on the pathogenesis, treatment and prevention of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (human and avian flu). More recently, he has also been interested in SARS-CoV-2 responsible for COVID-19 and the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has completed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work has already had a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections. 

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
393 entries « 2 of 40 »

Ramirez KA, Mond J, Papenburg J, Boivin G, Gilbert BE, Falsey AR, Bagga B, DeVincenzo JP

In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections

Journal Article

Virology, 586 , 2023.

Abstract | Links:

Lamothe G, Carbonneau J, Joly Beauparlant C, Vincent T, Quessy P, Guedon A, Kobinger G, Lemay JF, Boivin G, Droit A, Turgeon N, Tremblay JP

Rapid and Technically Simple Detection of SARS-CoV-2 Variants Using CRISPR Cas12 and Cas13

Journal Article

CRISPR J, 6 (4), 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, Hamelin MÈ, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

Journal Article

Influenza Other Respir Viruses, 17 (8), 2023.

Abstract | Links:

Pott H, Andrew MK, Shaffelburg Z, Nichols MK, Ye L, ElSherif M, Hatchette TF, LeBlanc J, Ambrose A, Boivin G, Bowie W, Johnstone J, Katz K, Lagacé-Wiens P, Loeb M, McCarthy A, McGeer A, Poirier A, Powis J, Richardson D, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, McNeil SA, ,

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)

Journal Article

Vaccine, 41 (42), 2023.

Abstract | Links:

Ghesquiere L, Boivin G, Demuth B, Giguere Y, Forest JC, Hamelin ME, Muckle G, Carbonneau J, Bujold E

Impact of COVID-19 and Vaccination During Pregnancy on Placenta-Mediated Complications (COVIGRO Study)

Journal Article

J Obstet Gynaecol Can, 2023.

Abstract | Links:

Pageau G, Levasseur M, Paniconi T, Jubinville E, Goulet-Beaulieu V, Boivin G, Jean J

The possibility of spreading herpes simplex virus type 1 via food handling and sharing

Journal Article

J Appl Microbiol, 134 (10), 2023.

Abstract | Links:

Racine É, Boivin G, Longtin Y, McCormack D, Decaluwe H, Savard P, Cheng MP, Hamelin MÈ, Carbonneau J, Tadount F, Adams K, Bourdin B, Nantel S, Gilca V, Corbeil J, De Serres G, Quach-Thanh C

The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers

Journal Article

Influenza Other Respir Viruses, 16 (5), 2022.

Abstract | Links:

Piret J, Goyette N, Boivin G

In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes

Journal Article

Antiviral Res, 202 , 2022.

Abstract | Links:

Uyar O, Dominguez JM, Bordeleau M, Lapeyre L, Ibáñez FG, Vallières L, Tremblay ME, Corbeil J, Boivin G

Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Piret J, Boivin G

Viral Interference between Respiratory Viruses

Journal Article

Emerg Infect Dis, 28 (2), 2022.

Abstract | Links:

393 entries « 2 of 40 »
Signaler des ajouts ou des modifications

Active projects

  • Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses, from 2023-03-01 to 2024-02-29
  • Changement de paradigme dans la conduite d'essais cliniques, from 2021-04-01 to 2024-03-31
  • CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal, from 2021-12-01 to 2024-03-31
  • Évaluation des interactions entre des virus respiratoires, from 2022-02-01 to 2025-01-31
  • Identification of innate immune pathways as targets for immunomodulatory therapy in herpes simplex virus encephalitis, from 2023-10-01 to 2028-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2024-03-31
  • Laboratoire international associé (LIA) sur la pathogenèse, le traitement et la prévention des infections virales respiratoires (LIA RespiVIR), from 2021-07-27 to 2026-07-26
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2024-03-31
  • Mise au point d'un modèle animal pour l'infection avec le virus parainfluenza-3, from 2024-01-10 to 2026-01-10
  • Plateforme de laboratoire de niveau de confinement 3 pour la recherche sur les virus émergents, from 2023-01-31 to 2025-03-31
  • Relationship between COVID-19 and Parkinson’s disease in a mouse model, from 2022-10-01 to 2024-03-31

Recently finished projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, from 2016-07-01 to 2023-06-30
  • COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal, from 2021-12-01 to 2022-11-30
  • Évaluation de l'efficacité des probiotiques sur les affections post-COVID-19. , from 2021-06-01 to 2022-03-31
  • Évaluation du potentiel thérapeutique de la protectine DX et d'analogues contre la COVID-19 , from 2020-06-01 to 2022-03-31
  • Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE), from 2020-11-01 to 2022-09-30
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, from 2018-10-01 to 2022-09-30
  • Modulation des réponses immunitaires à la vaccination contre la COVID-19 par une intervention sur le microbiote intestinal : un essai randomisé contrôlé, from 2021-04-01 to 2022-03-31
  • Plateforme de laboratoire de niveau de confinement 3 respiratoire, from 2020-03-25 to 2022-03-27
  • Projet du Groupe québécois de recherche sur l'infection périnatale à COVID-19 (Banque de données des grossesses COVID-19), from 2020-04-01 to 2022-03-31
  • Sentinel Surveillance for Severe Outcomes of Laboratory-Confirmed Influenza in Adults for the Annual Influenza Season and for Confirmed and Suspected Cases Of Covid-19/Sars-Cov-2 Acute Respiratory Disease, Covid-19 Vaccine Effectiveness and, from 2022-04-01 to 2023-03-31
  • Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), from 2020-04-01 to 2022-03-31
  • SO05 QC07, Sentinel surveillance for confirmed and suspected cases of covid-19/covsars-2 acute respiratory disease, covid-19 vaccine effectiveness and adverse events following sars-cv-2 vaccines: A study of the Serious Outcomes Surveillance, from 2021-04-01 to 2023-09-30
Data provided by the Université Laval research projects registery